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1. Introduction  
As knowledge about the cellular and molecular mechanisms that control vessel growth 
grew during the last two decades, therapeutic manipulation of angiogenesis was 
increasingly regarded as one of the most promising areas of translational research. Based on 
its potential to target key steps in the pathogenesis of disease groups with great impact on 
public health, therapeutic blockage and stimulation of angiogenesis emerged years ago, as 
the holy grail of research on new strategies to treat cancer and arterial occlusive diseases 
respectively. However, the result of these two related development processes were quite 
different. Anti-angiogenic therapy is today a reality in the treatment of cancer and diseases 
associated with pathological vessel growth such in the retina. In contrast, no strategy based 
on the concept of stimulating angiogenesis (usually referred as “therapeutic angiogenesis”) 
has so far reached widespread clinical use. 
1.1 The clinical problem: critical limb ischemia 
Arterial occlusive disease (AOD) is the leading cause of morbidity and mortality in 
industrialized countries, and represents a problem of growing dimensions for developing 
countries (Beaglehole et al., 2003). Clinically, AOD includes acute myocardial infarction, 
stroke and peripheral arterial disease (PAD). PAD is defined as the obstruction of arterial 
blood flow, in areas other than  the brain and heart (Garcia, 2006). When it affects the lower 
limbs, the clinical picture is silent in its early stages, progressing to intermittent claudication 
when the obstruction of blood flow reaches 50% of normal. Out of patients with intermitent 
claudication, between 15 and 20% are estimated to progress to critical limb ischemia (CLI) 
(Dormandy et al., 1989; Second European Consensus Document, 1991). The term critical 
limb ischemia (CLI) refers to the final stages of PAD, when chronic lack of blood supply sets 
off a cascade of pathophysiologic events that lead to rest pain, trophic lesions of the leg or 
both (Varu et al., 2010). The international consensus definition of CLI is the following: any 
patient with chronic ischemic rest pain, ulcers, or gangrene attributable to objectively 
proven arterial occlusive disease (Norgren et al., 2007). CLI patients represent 
approximately 1% of patients with PAD. The prognosis of these patients can be compared to 
some other malignancies, showing overall survival rates below 50% in 5 years 
(DormandyThomas, 1988).  
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The diagnosis of established CLI is straightforward, and based on the physical examination, 
the ankle:brachial index (ABI), and on several imaging methods. Despite progresses in 
medical care, the grim significance of CLI diagnosis does not seem to have changed 
significantly during the last decade, remaining a predictor of poor survival and poor 
outcomes (Varu et al., 2010). Observational studies of patients with CLI roughly agree on a 
50% amputation-free rate after 1 year (with part of these patients still presenting symptoms), 
25% of patients undergoing a major amputation and 25% will have died. In areas with 
poorer medical care, these numbers maybe even worse.   
Current treatment of CLI is complex, involving both surgical and non-surgical approaches. 
The goal of treatment is to restore adequate blood supply. Ultimately, success should 
include relief of ischemic pain, healing of ischemic ulcers, prevention of limb loss, 
improvement of patient function and quality of life, while also prolonging survival.  
Revascularization, either surgical or endovascular, is the most straightforward and intuitive 
strategy to reach these goal. Unfortunately, revascularization is not always feasible for 
several reasons. First, CLI is not only a disease of large vessels, and widespread 
microvascular and/or surrounding tissues involvement at the time of diagnosis (resulting in 
poor outflow vessels in the limb) may hamper its success. Second, medical comorbidities, 
invariably present in CLI patients, may also limit surgery as a viable option. Last, even in 
patients referred to surgical revascularization, an extremely high immediate post-operative 
mortality rate that reaches 11.6% according to a recent meta-analysis (Albers et al., 2006) 
demonstrates the need for a thorough assessment of risks and benefits, underscoring the 
challenge of treating CLI. For patients for whom revascularization is not feasible for one of 
these reasons, limb loss rates after 6 months are near 50% (Brass et al., 2006), and 
amputation remains as the only option to treat CLI.  
In conclusion, CLI  represents a condition characterized by considerable morbidity and 
mortality, a high impact on quality of life, and suboptimal treatment options. These 
characteristics highlight the importance of devising new strategies to treat CLI.  
1.2 Understanding the problem: pathophysiology of CLI 
From a pathophysiological stand-point, CLI affects both macrovascular and microvascular 
systems, and is characterized by chronic deprivation of blood supply to limb tissues. With 
time, several changes in the structure and function of the vascular tree occur, including 
diminished sensitivity to vasodilatory stimuli, decreased wall to lumen ratio, lower nitric 
oxide production, and capillary microthrombi formation due to impaired anticoagulant 
function of the endothelium (Varu et al., 2010).  
The natural response to tissue ischemia is the activation of several molecular and cellular 
pathways that result in the formation of new blood vessels, involving processes such as 
angiogenesis and arteriogenesis. However, in CLI patients, as in other forms of AOD, this 
response is not sufficient to provide the adequate amount of blood to ischemic tissues.  
2. Therapeutic angiogenesis 
Thirty years ago, Folkman observed that the development and maintenance of an adequate 
microvascular supply is as an essential condition for growth of neoplastic tissue (Folkman, 
1971), laying the ground for the development of anti-angiogenic therapies and also for 
therapeutic angiogenesis. Later, the idea of boosting the formation of collateral vessels as a 
way to treat CLI, a strategy known as "therapeutic angiogenesis", was stimulated by 
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angiographic and clinical observation that spontaneous development of collateral vessels 
was sufficient to preserve ventricular function in patients with ischemic heart disease 
(Habib et al., 1991). Therefore, it was not very long after the identification of the first 
angiogenic growth factors that the first experiments using Vascular endothelial growth 
factor (VEGF-A) were initiated, aiming to improve blood flow to ischemic tissues (Takeshita 
et al., 1994).  
2.1 The rationale for therapeutic angiogenesis 
For therapeutic angiogenesis to be justified from a theoretical standpoint, at least one of the 
following two conditions must be true: (1) the presence of decreased levels of angiogenic 
growth factors in ischemic tissues, or (2) the possibility of optimizing the endogenous 
response to ischemia through the use of supra-physiological doses of these factors. 
Regarding the first hypothesis, Schultz and colleagues demonstrated a positive correlation 
between the expression of VEGF-A stimulated by hypoxia in monocytes and the number of 
collaterals in the myocardium of patients with chronic coronary ischemia (Schultz et al., 
1999). Furthermore, senile rabbits and mice exhibit subnormal angiogenic response, 
attributed to decreased levels of VEGF-A in ischemic tissues, and supplementation with 
exogenous VEGF-A reversed this  subnormal angiogenic response (Rivard et al., 1999). A 
single study that evaluated the concentrations of these factors in muscle and skin of patients 
with PAD found normal levels of VEGF-A, and high levels of other angiogenic growth 
factor FGF-2, suggesting a relative deficiency of VEGF-A in these tissues (Palmer-Kazen et 
al., 2004). Regarding the second hypothesis, several studies have shown that 
supraphysiological doses of VEGF optimize the angiogenic response (Post et al., 2001), and 
this was indeed the rationale for most of the initial protocols for therapeutic angiogenesis. It 
should be noted however, that supraphysiological doses of VEGF-A and FGF-2 have also 
been shown to induce the formation of aberrant vessels (Sola et al., 1997; Ozawa et al., 2004), 
suggesting that the therapeutic window for this strategy may be narrow. For this reason, a 
detailed comprehension of the molecular and cellular events that govern the formation of 
new blood vessels is of paramount importance for the development of a successful 
therapeutic angiogenesis strategy. 
2.2 The “how-to” of new blood vessels formation 
In the human embryo, development of the vascular system begins with the formation of the 
blood islands, where hematopoietic and endothelial cell (EC) precursors (angioblasts) 
coexist (Choi et al., 1998). The differentiation of angioblasts in EC is called vasculogenesis, 
and is the process by which  primitive tubes of EC are formed. Several additional steps are 
needed until a functional and mature vascular system is formed. During these processes, 
vascular sprouts emerge from pre-existing tubes, a process known as angiogenesis, and 
mural cells (pericytes and smooth muscle cells - SMC) are incorporated, a process termed 
arteriogenesis (Conway et al., 2001). The regulation of these steps is made through a 
complex network of vascular growth factors. To mention some, VEGF plays a critical role 
from early to later stages, which was demonstrated in knockout mice for the VEGF gene, 
which do not develop a vascular system (Carmeliet et al., 1997). Moreover, in an unusual 
observation, heterozygosity for the VEGF gene (+/-) determined the mortality of all 
animals, indicating the need for optimal concentrations of VEGF for vascular formation. The 
expression of VEGF occurs, among other stimuli, in response to hypoxia (Shweiki et al., 
1992). It is now recognized that hypoxia induces expression of HIF-1, which binds to a 
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promoter region of VEGF gene, driving its expression in ischemic areas (Kimura et al., 2000). 
FGF is another growth factor that promotes the proliferation and migration of EC. PDGF is 
essential for the recruitment of components of the vascular wall such as SMC, that stabilize 
EC by preventing their unregulated proliferation (Benjamin et al., 1998). Angiopoietin 1 is 
involved in the maintenance of vascular integrity (Thurston et al., 1999) and recruitment of 
smooth muscle cells (Suri et al., 1996). In conclusion, the formation of a mature arterial 
system starts with the proliferation of EC (vasculogenesis), followed by the sprouting of 
new capillaries (angiogenesis), and the maturation of the newly formed vessel by pericytes, 
smooth muscle cells and extracelular matrix (arteriogenesis).  
Angiogenesis also occurs in post-embryonic life, in physiological situations such as the 
ovulatory cycle, wound healing, and in response to tissue ischemia, as in CLI. In addition, 
several pathological conditions are associated with increased angiogenesis, such as 
inflammation, proliferative retinopathy and growth and spread of tumors (Carmeliet, 2003). 
In general terms, it is acknowledged that post-natal angiogenesis recapitulates the 
mechanisms described in the embryo. 
2.3 Gene therapy as the preferred platform for therapeutic angiogenesis 
One of the most attractive aspects of therapeutic angiogenesis is that by increasing the 
formation of collateral vessels, one would be only intensifying what happens spontaneously 
in ischemic tissue. The simplicity of this idea, associated with the huge unmet needs of 
patients with CLI, resulted in a relatively rapid transition from preclinical to phase I and II 
trials, which were initiated with a level of expectation that was probably too unrealistic 
considering the amount of basic and translational research on post-natal angiogenesis 
available at that time.  
Gene transfer was rapidly considered the preferred method for therapeutic angiogenesis. 
Using gene therapy (GT), genes of vascular growth factors could be directly injected into 
ischemic muscle, which would function both as the major therapeutic target, as well as a 
production site for these proteins. Several reasons make CLI an attractive target for GT. 
These include not only the limitations of available treatments for CLI, but also a series of 
very specific characteristics of CLI treatment that will be discussed next.  
2.3.1 Requirement of lower levels of expression 
A major obstacle to the success of GT in some hereditary diseases is the need to obtain high 
and sustained expression of the therapeutic gene. Initial observations suggested that 
therapeutic angiogenesis required minimal and only transient expression of angiogenic 
growth factors (Dor et al., 2002). This was interpreted as a possibility to obtain therapeutic 
effects with less and more simple vectors, resulting in higher safety, and lower costs.  
2.3.2 Availability of animal models 
The existence of animal models that reproduce the clinical outcome of CLI allowed the 
completion of preclinical studies and accelerated the development of clinical trials. In this 
model, hindlimb ischemia is generated by excision of the femoral artery of the animal 
(usually rabbit or rat) leg (Pu et al., 1993).  
2.3.3 Expression of naked DNA by skeletal muscle 
Perhaps the most important factor to boosted studies in GT-based therapeutic angiogenesis 
from the 90’s on was an  intriguing observation in 1990 by Wolff and colleagues, that pure 
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DNA or RNA could be absorbed and expressed by skeletal muscle cells of mice without the 
participation of any particular system of gene transfer (Wolff et al., 1990). Although the 
mechanism of DNA capture by the target cell remains unknown (Wolff et al., 2005), the 
confirmation of this observation opened the way for the use of non-viral vector (usually in 
the form of pure plasmid DNA) in CLI studies.  
2.3.4 Lower complexity of strategies based on non-viral vectors  
The major advantage of non-viral vectors is their safety profile. These vectors do not 
integrate into the host genome (no risk of insertional mutagenesis), do not trigger severe 
inflammatory reactions (absence of innate immune response to the vector), which would be 
a huge limitation in an already inflamed tissue, and their effectiveness is not limited by 
previous immunity of the host. In addition, non-viral vectors are simple to produce, at lower 
costs when compared to viral vectors.  
3. Preclinical data 
Using variations of the model of hind limb ischemia (Pu et al., 1993), the effectiveness of 
therapeutic angiogenesis in small animal models was demonstrated by intra-arterial, 
intravenous and intramuscular administration of recombinant proteins or by gene transfer 
of several vascular growth factors (Takeshita et al., 1994; Takeshita et al., 1994; Bauters et al., 
1995; Tsurumi et al., 1996; Garcia-Martinez et al., 1999; Shimpo et al., 2002). However, as 
discussed in the next section, these studies should be regarded more a proof of concept tool 
than as an indicator of efficacy in clinical studies.  
In order to have a more critical view of these studies, it is important to briefly review 
general characteristics of the hindlimb ischemia model and of tools to evaluate efficacy in 
these studies. 
3.1 The hindlimb ischemia model 
In the classic hindlimb ischemia model, ligation and excision of the iliac or femoral artery 
reduces blood flow to levels between 30%, inducing a series of events that trigger 
angiogenesis and arteriogenesis over 3-4 weeks, after which resting blood flow is restored to 
about 60-70% of baseline (Scholz et al., 2002). In order to more accurately reproduce the 
progressive clinical course of CLI, a minority of studies used stepwise ligation of vessels, as 
well as constricting devices (Tang et al., 2005). Angiographic study of these animals show 
that collaterals emerging from the side branches of internal iliac artery and reaching the 
distal portions of the foot, as well as an extensive network of capillaries throughout the 
ischemic muscle are responsible for the partial restoration of blood flow (Takeshita et al., 
1997). Because revascularization in this model has been shown to involve the basic 
mechanisms of angiogenesis and arteriogenesis (Asahara et al., 1997; Scholz et al., 2002), the 
model has been widely used in preclinical studies of GT-based therapeutic angiogenesis. 
However, one should acknowledge that the model does not exactly mimic the slow 
progression of atherosclerosis observed in patients with PAD. In addition, revascularization 
that occurs in this model is associated with intense capillary proliferation, whose real 
significance for perfusion has been challenged.  
As in other areas of medical research, the translation of results from small animal models to 
humans is problematic. This is even more relevant for studies using gene transfer by direct 
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injection of non-viral vectors. Uptake and expression of non-viral vectors by skeletal muscle 
occurs mostly in the vicinity of the needle (Wolff et al., 1990). Therefore, the exposure of 
muscle fibers to vector is much higher in rats and rabbits, than in humans, even if multiple 
injections are used in humans. In addition, animals used in these studies are usually healthy 
and young, as opposed to patients with CLI. This is even more relevant because it has been 
shown that age impairs the angiogenic response (Zhuo et al., 2010).  
3.2 Methods used to evaluate efficacy 
Although the preclinical studies have unequivocally demonstrated that GT-based 
therapeutic angiogenesis increase capillary proliferation in ischemic tissues, the real 
significance of this increase to the effective perfusion remains uncertain. Thus, the use of 
functional methods to assess the clinical relevance of newly formed vessels is of utmost 
importance in preclinical studies. Usually, efficacy is measured by a combination of 
anatomic (usually counting of newly formed vessels in histological sections or angiographic 
studies) and functional methods. Perfusion studies with microspheres that are trapped in 
capillaries are considered the gold-standard, bur are time-consuming. Therefore, doppler 
tissue imaging, which measures the skin blood flow in the ischemic limb, is one of the most 
frequently used functional method. The method is based on the assumption that skin 
perfusion reflects whole limb perfusion. Alternative methods such as measurements of 
oxygen tension, sestamibi scintigrapy and heat detecting cameras have also been used, 
along with clinical scores that evaluate the presence of ulcer healing, necrosis, etc. 
Whichever the method used, one should bear in mind potential pros and cons to avoid over-
interpretation of preclinical data.  
4. Data from clinical trials 
In humans, GT-based therapeutic angiogenesis was first used in 1994 in a patient with CLI, 
who received an intra-arterial (distal to the obstruction) injection of plasmid DNA 
containing the cDNA of VEGF-A (Isner et al., 1996). The authors reported angiographic 
improvement after 12 weeks, associated with the development of angiomas and unilateral 
edema, two characteristics that enforced the biological effect of the treatment. The first 
phase I study also used plasmid DNA of the VEGF-A cDNA, delivered by multiple 
intramuscular injections in 9 CLI patients for whom revascularization was not feasible. 
Treatment was considered safe, and transient edema was the only adverse event. In 
addition, the authors reported increased levels of VEGF-A in serum, and improvements in 
ABI and in skin lesions, which could avoid amputation in 3 patients (Baumgartner et al., 
1998). Two years later similar results were reported by the same group in 50 patients 
(Baumgartner et al., 2000). Subsequently, additional phase I studies confirmed the safety of 
these strategies (Comerota et al., 2002), paving the way for phase II studies.  
4.1 Phase II studies 
The first randomized double-blind study involved 54 patients with PAD amenable to 
angioplasty. In this study, VEGF-A gene transfer (n=35) or placebo (n = 19) were delivered 
intra-arterially by catheter after angioplasty. Gene transfer was performed using adenovirus 
(n=18) or non-viral vectors (liposome/plasmid-DNA) (n=17). Treatment proved to be safe. 
However, despite s significant increase in the number of collaterals in the two treated 
groups compared to placebo, other efficacy parameters were not modified (Makinen et al., 
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2002). In the second randomized doubleblind study, 54 patients with CLI and diabetes were 
randomized to intramuscular injections of placebo or plasmid DNA with the VEGF-A 
cDNA. The primary efficacy endpoint (amputation at 100th day) was not significantly 
modified by treatment, but authors reported significant improvements in ABI, and in ulcer 
healing in treated patients compared to placebo (Kusumanto et al., 2006). Though not using 
non-viral vectors, the RAVE (Regional Angiogenesis with Vascular Endothelial Growth 
Factor) trial deserves to be discussed. In this trial, 105 patients with unilateral, exercise-
limiting claudication were randomized to directi intramuscular injections of low or high 
doses of adenoviral VEGF121 (Kusumanto et al., 2006). Despite the observation of dose-
dependnent peripheral edema, which suggests that bioactive VEGF was indeed produced, 
the authors observed no significant change in primary or secondary endpoints. These results 
raised several important questions: First, it could be possible that the use of an isoform of 
VEGF that could have a shorter tissue half-life (as is the case of VEGF121 compared to 
VEGF165) could have limited treatment efficacy. Alternatively, the lack of validated 
endpoints, privileging physician-oriented as opposed to patient-oriented outcomes could 
also explain the negative results. Finally, failure could simply mean that use a VEGF isolated 
is not an effective strategy to obtain clinicaly-relevant therapeutic angiogenesis in CLI 
(Gupta et al., 2009).   
After the first phase I trial with gene transfer of FGF-1 reported improvements in wound 
healing, pain and transcutaneous oxygen pressure after intramuscular injection of naked 
plasmid FGF-1 (Comerota et al., 2002), results from a phase II trial were reported. In this 
trial (TALISMAN 201 phase II trial in patients with CLI), patients were randomized to 
intramuscular injections of NV1FGF (n=59) or placebo (n=66) (Nikol et al., 2008). After 25 
weeks, the proportion of patients that reached the primary endpoint (ulcer healing) did not 
differ significantly between treatment and control groups. However, amputation rate was 
significantly lower in NV1FGF-treated patients compared to placebo (37.3 vs 55.4%) and the 
strategy moved on to a phase III trial.     
Because of its properties to regulate the expression of multiple downstream mediators of the 
angiogenesis cascade, including VEGF, thus acting as a “master-switch” agent, the 
transcription factor hypoxia-inducible factor (HIF) 1- has been intesively studied as a 
candidate therapeutic gene for therapeutic angiogenesis (Gupta et al., 2009).  
The most extensively studied growth factor that is currently under clinical development for 
GT-based therapeutic angiogenesis is hepatocyte growth factor, a potent mitogen for several 
cell types (Bussolino et al., 1992). It has been shown that serum levels of HGF are elevated in 
patients with coronary artery disease, and that higher levels correlate with better prognosis 
(Lenihan et al., 2003). In the STAT phase II trial, 104 patients with CLI were randomized to 
treatment with placebo or HGF (Powell et al., 2008). No safety concerns were raised related 
to the therapeutic agent. On an intention-to-treat analysis, no significant differences in 
transcutaneous oxygen tension (TcPO2) were observed among patients treated with HGF (in 
increasing dose levels) or placebo. However, when patients that presented increases in 
TcPO2 before treatment were excluded, patients that received the highest dose level of HGF 
presented significant improvements in TcPO2 compared to the remaining groups. Again, 
these observations demonstrate the impact of endpoint selection in trial results and 
highlight the importance of identifying the most relevant endpoint to be used in therapeutic 
angiogenesis trials.  
Following this study, the same group recently reported the results of the HGF-0205 trial. 
Patients received three sets of eight intramuscular injections of HGF plasmid every 2 weeks 
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(Powell et al., 2010). Injection sites were selected on an individual basis based on 
arteriographically defined vascular anatomy. In total, 21 patients were randomized to HGF 
treatment and 6 to placebo. No safety concerns were raised. HGF-treated patients presented 
significant improvements in toe-brachial index and rest pain compared to patients that 
received placebo. Complete ulcer healing at 12 months occurred in 31% of patients 
compared to 0% of placebo, though this difference was not statistically significant. 
Amputation rates (HGF 29 % vs. placebo 33%) and mortality were similar between groups. 
These results suggest that tailoring treatment to patient indivual characteristics might 
improve treatment outcomes. If confirmed, it is possible that the classical strategy to inject 
naked DNA into predefined sites of ischemic tissue with poor knowledge of the 
pharmacological and geographic distribution of the actual treatment agent could justify 
several negative results reported in previous human trials. One should bear in mind that 
when using a delivery strategy that is characterized mostly by local transfection, the 
proportion of ischemic tissue actually treated in a mouse or rat is very unlikely to be reached 
even by multiple injections in humans.        
Additional studies have been recently reported using HGF plasmid-based therapeutic 
angiogenesis. In a multicenter, randomized, double-blind, placebo-controlled trial, 40 
patients also received injections in sites selected by angiographic evaluation, on days 0 and 
28 (Shigematsu et al., 2010). The overall primary improvement rate of the primary endpoint 
(improvement of rest pain or reduction of ulcer size) was significantly higher in HGF-
treated patients (70.4%) compared to the placebo group (30.8%). An evaluation of quality of 
life also showed benefits of HGF treatment. Very recently, HGF plasmid intramuscular 
injections was also shown to improve several efficacy endpoints such as ABI, ulcer size, 
pain,  in another phase I/IIa trial that treated 22 patients with CLI with of 2 or 4 mg of HGF 
plasmid, 2 times (Morishita et al., 2011).    
Finally, a phase II trial was also conducted using gene transfer of an extracellular matrix 
protein that induces angiogenesis indirectly  by interaction with integrins,  Developmentally 
regulated endothelial locus (Del-1). In the DELTA trial, 105 patients with PAD were 
randomized to intramuscular injections of Del-1 plasmid in association with poloxamer 188, 
an agent that enhances transfection (Grossman et al., 2007). The control group received 
poloxamer 188 alone. No safety concerns were raised, but neither primary nor secondary 
endpoints were modified. Notably, improvement in these endpoints occurred in both 
treated and control groups, highlighting the importance of placebo effect in studies using 
new strategies such as gene therapy.  
4.2 Safety concerns 
To date, more than 1000 subjects have been treated for gene therapy for therapeutic 
angiogenesis in phase I and II trials, with adverse event rates that are similar to those  in 
control groups (Varu et al., 2010). Still, there are important long-term safety concerns, 
stemming from theoretical but rather intuitive and important considerations, that still need 
to be addressed and weighted against the benefits of gene therapy-based therapeutic 
angiogenesis. These include the risk of accelerating pathologic angiogenesis in tumors, 
retina and atherosclerotic plaques.  So far no evidence of these effects has been reported. 
Dose-dependent hypotension or proteinuria (> 1g/24h) have been reported in studies using 
VEGF-A (Henry, Rocha-Singh et al., 2001) and FGF-2 (Laham et al., 2000; Unger et al., 2000; 
Cooper et al., 2001) in the form of recombinant proteins, but in studies with gene therapy, 
where lower levels of proteins are expected to be expressed, these were not observed. 
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Studies with hepatocyte growth factor have not raised significant safety concerns. Of note, 
in one recent study, circulating levels of HGF were not detected, suggesting a restricted 
distribution of the therapeutic agent (Morishita et al., 2011).  
5. Next steps 
Preclinical and clinical trials have demonstrated the safety and potential efficacy of this 
strategy. Currently, the area is going through a phase in which new strategies and 
conceptual changes, developed after reevaluation of early clinical results and after a return 
from bedside to bench, are being tested in clinical trials. After almost 2 decades since the 
first human trial of GT for CLI, it is clear that  several factors can be optimized in order to 
maximize the effectiveness of therapeutic angiogenesis. These include:  
 Animals x humans: differences between animal models and the progression of CLI in 
humans, should be acknowledged, thus avoiding over-interpretation of results from 
animal studies.  
 Efficacy outcomes (animals): more relevant efficacy outcomes should be identified in 
preclinical models allowing more realistic translation of results from bench to bedside. 
 Efficacy outcomes (humans): CLI is diagnosed and monitored with the help of objective 
methods that include ABI determination, toe systolic pressures or transcutaneous 
partial pressure of oxygen (TcPO2) (Varu et al., 2010). However, an important 
unanswered question that makes evaluation of treatment even more complex is the 
very definition of a salvageable versus a non-salvageable limb (Connelly et al., 2001; 
Rowe et al., 2009). As in other areas of medical research, treatment outcome measures 
are mostly physician- rather than patient oriented. In the context of CLI, outcomes such 
as ABI improvement, limb salvage and survival have always been considered the most 
significant outcomes that any new treatment should be able to improve. However, 
patient-oriented outcome research in the last years suggests that in selected populations 
these outcomes are not necessarily associated with improvements in quality of life 
(Varu et al., 2010). Whether classical outcomes such as ABI index, or more patient-
oriented outcomes should be used as primary endpoint for efficacy assessment of 
therapeutic angiogenesis is an important and challenging question. 
 Basic science: Continuing research efforts on the mechanisms of blood vessel formation 
are extremely important to allow more rational selection of therapeutic genes to treat 
CLI. These could include the use of “cocktails” of growth factor genes, or master-switch 
genes, that could induce an angiogenic response that is closer to that spontaneously 
observed during “physiologic” collateral formation.  
 Delivery strategies and vectors: Better delivery strategies and/or more efficient non-viral 
vectors for GT-based therapeutic angiogenesis should be developed, allowing more 
widespread expression of the therapeutic gene in human skeletal muscle. 
 Towards a pharmacological approach to therapy: Better understanding of variables that 
govern the pharmacokinetics of non-viral vector delivery to skeletal muscle, thus 
enabling a less empiric design of clinical trials are of paramount importance so that trial 
design with non-viral vectors delivered to skeletal muscle start to move towards a more 
pharmacological paradigm, that allow a more rational interpretation of data and 
planning of treatment. So far, actual “dosing” of the therapeutic proteins has not been 
possible. In fact, this could severely affect the possibility to to reproduce even very 
positive results in larger scale phase III trials.  
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Therapeutic manipulation of angiogenesis is increasingly regarded as a promising treatment 
alternative for patients with CLI, as results from a new generation of clinical trials are 
revealed. The rationale for the use of vascular growth factors to stimulate vessel growth in 
ischemic tissues is mainly the demonstration that ischemic tissues present a relative 
deficiency of these growth factors, and that their administration can boost vessel growth. In 
addition, several characteristics render CLI a very interesting target for gene therapy-based 
therapeutic angiogenesis. In this chapter we reviewed the molecular and cellular rationale of 
therapeutic angiogenesis, results from pre-clinical studies, and finally results from clinical 
trials that used gene therapy as a platform for therapeutic angiogenesis. In addition, we 
tried to provide a critical appraisal of limitations of small animal models (and of the 
translation of endpoints from these studies to clinical practice), as well as a discussion on the 
steps that still need to be taken in order to render gene therapy with non-viral vectors as a 
more predictable and controllable strategy. 
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